Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease : a multicenter, randomized, double-blind, placebo-controlled clinical trial
Bañares, Juan (Vall d'Hebron Institut de Recerca (VHIR))
Aceituno, Laia (Vall d'Hebron Institut de Recerca (VHIR))
Ruiz-Ortega, Lourdes (Vall d'Hebron Institut de Recerca (VHIR))
Pons Delgado, Mònica (Vall d'Hebron Institut de Recerca (VHIR))
Abraldes, Juan G. (University of Alberta)
Genescà Ferrer, Joan (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2024
Resum:	Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.
Ajuts:	Instituto de Salud Carlos III PI21/00691
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cirrhosis ; First decompensation ; Hepatocellular carcinoma ; Portal hypertension ; Zinc
Publicat a:	Hepatology Communications, Vol. 8 (october 2024) , ISSN 2471-254X

DOI: 10.1097/HC9.0000000000000524
PMID: 39392768

9 p, 501.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats